Filter posts

Trubion reports positive data from Phase 2B TRU-015 study

Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced favorable safety and efficacy data following administration of a …

Rexahn reports Phase IIa data for Serdaxin

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) announced top-line results from a Phase IIa clinical study …

Endocyte announces close of $26 million equity financing

Endocyte, Inc., completed a $26 million extension of its Series C financing. This round included …

Targacept reports positive Phase 2b trial results for depression treatment

Targacept, Inc. (NASDAQ: TRGT) presented data from its Phase 2b clinical trial of TC-5214 as …

Q&A with ExonHit Therapeutics’ Loïc Maurel, MD

We recently spoke with Loïc Maurel, M.D., president of ExonHit Therapeutics’ Management Board, one of …

Inovio begins HIV clinical trial of DNA vaccine

Inovio Biomedical Corporation (NYSE Amex: INO) and the HIV Vaccine Trials Network (HVTN) initiated a …

Methylgene to receive equity investment from Otsuka Pharmaceutical

MethylGene Inc. (TSX: MYG) agreed to issue 3,686,182 common shares to Otsuka Pharmaceutical Co., Ltd. …

Provectus starts compassionate use program for PV-10

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) expanded its compassionate use program for PV-10, making the agent, …

Positive Palifosfamide Sarcoma Phase II Data from ZIOPHARM

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced positive data from the multicenter randomized Phase II trial …

Positive clinical trial results for Epeius

Epeius Biotechnologies Corporation announced results of its Rexin-G®  clinical trials. Administered as stand-alone therapy in …